IGC Pharma's TGR-63 Shows Dual-Target Activity Against Alzheimer's Pathology in Preclinical Studies
Key Insights
IGC Pharma (search) announced preclinical data showing TGR-63 inhibits both beta-amyloid plaque aggregation and tau protein fibril formation at micromolar concentrations.
The investigational small-molecule candidate demonstrated serum stability under physiological conditions and was detectable in serum samples at 1 and 24 hours post-administration.
TGR-63's dual mechanism of action targeting two central drivers of Alzheimer's pathology distinguishes it from current single-target therapies.
IGC Pharma (search) has announced preclinical findings demonstrating that its investigational small-molecule candidate TGR-63 exhibits dual therapeutic activity against key pathological hallmarks of Alzheimer's disease. The data show that TGR-63 not only disrupts beta-amyloid (Aβ) plaque aggregation, as previously reported, but also inhibits tau protein aggregation, addressing two central drivers of Alzheimer's pathology.
Dual Mechanism of Action Validated
In vitro assays revealed that TGR-63 suppresses tau fibril formation at micromolar concentrations, suggesting its ability to interfere with the development of neurofibrillary tangles that are strongly associated with neuronal dysfunction and cognitive decline. This tau-targeting activity complements the compound's previously demonstrated effectiveness in disrupting Aβ plaque aggregation.
"These results underscore the potential of TGR-63 as a differentiated, dual-acting candidate that targets both beta-amyloid and tau, two central drivers of Alzheimer's pathology," said Ram Mukunda, CEO of IGC Pharma (search). "By broadening our portfolio with this important addition, we are strengthening IGC's capabilities in developing safer and more effective therapies that go beyond the limitations of current treatments."
Pharmacological Stability Confirmed
Serum stability studies demonstrated that TGR-63 retains its structural integrity under physiological conditions. The compound remained stable when incubated in phosphate-buffered saline (PBS) and mouse blood serum at 37°C for several hours. MALDI mass spectrometry analysis further detected TGR-63 in serum samples at both 1 and 24 hours post-administration, supporting its pharmacological resilience and systemic delivery potential.
Clinical Development Strategy
The dual mechanism of action findings are protected under IGC Pharma (search)'s patent portfolio, positioning the company to advance TGR-63 through continued preclinical development. The goal is to establish a novel, disease-modifying approach to Alzheimer's treatment that differs from current single-target therapies.
Mukunda emphasized the company's commitment to developing "truly disease-modifying solutions for Alzheimer's" as they continue preclinical evaluation of TGR-63. The clinical-stage biotechnology company leverages AI to develop innovative treatments for Alzheimer's and metabolic disorders, with its lead asset IGC-AD1, a cannabinoid-based therapy, currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia.